Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05365360 · ClinicalTrials.gov registry record · NA
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
A NA study of Androgenetic Alopecia, sponsored by University of Arizona.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05365360: Recruiting NA study of Androgenetic Alopecia, sponsored by University of Arizona.
NCT05365360 is a NA study of Androgenetic Alopecia that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 50 participants, below the 162-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05365360, a NA study of Androgenetic Alopecia, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical minoxidil and oral finasteride1. In addition to medical therapies, FDA-cleared medical devices are now utilized for the treatment of AGA as of 20072. These devices, termed low level laser therapy (LLLT), come in multiple forms including combs, helmets and sports cap wearable devices2. These home-use, wearable devices utilize the \~650 nm wavelength laser light to stimulate the hair follicle mitochondria and thereby promote hair growth, a process termed "photobiomodulation"3. Recent meta-analyses investigating photobiomodulation and LLLT for AGA have noted an increase in fluence or energy delivered per cm is associated with increased hair density3. However, randomized control trials (RCT) with direct comparison of LLLT devices of different fluences has yet to be performed. Accordingly, in the present study we aim to investigate if increasing fluence in LLLT devices is associated with increased hair density by comparing sham LaserCap to LaserCap SD (1.15 J/cm2, low fluence) and LaserCap HD+ (3.93 J/cm2, high fluence) in RCT.
Conditions Studied
Interventions
- DEVICE LaserCap SD
- DEVICE Sham LaserCap
- DEVICE LaserCap HD+
Study Locations (1)
Arizona
- Banner University Dermatology - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2025-05 |
| Phase | NA |
What NCT05365360 shows while recruiting
NCT05365360 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 162-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Androgenetic Alopecia appearing as the primary indexed condition, and to 3 interventions - of which LaserCap SD is the first listed.
NCT05365360 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT05365360 about?
NCT05365360 is a clinical study titled "Sham LaserCap vs. LaserCap SD vs. LaserCap HD+". Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical minoxidil and oral finasteride1. In addition to medical therapies, FDA-cle...
What is the current status of trial NCT05365360?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-06-01. Estimated completion is 2025-05.
What conditions does trial NCT05365360 study?
This clinical trial studies the following conditions: Androgenetic Alopecia.
What interventions are being tested in trial NCT05365360?
The interventions under investigation include: LaserCap SD (DEVICE), Sham LaserCap (DEVICE), LaserCap HD+ (DEVICE).
Who is sponsoring clinical trial NCT05365360?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05365360 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05365360's enrollment target sits among peer trials
50 8th of 16 higher than 9 of 16 other Androgenetic Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Androgenetic Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
RECRUITING · NA
-
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
COMPLETED · NA
-
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
COMPLETED · NA
-
Computer-Assisted Versus Manual Hair Harvest Comparative Study
COMPLETED · NA
-
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
COMPLETED · NA
-
A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI